Hai cercato: 4-Amino-6-hydroxy-2-methylpyrimidine+dihydrate

52 343 risultati sono stati trovati

Perfeziona la ricerca Seleziona per

Sort Results

Visualizzazione a lista Nuova Visualizzazione

Compara(0) Cancella

La tua valutazione

4-Amino-6-hydroxy-2-methylpyrimidine dihydrate ≥98%

Fornitore: Thermo Scientific

Descrizione: 4-Amino-6-hydroxy-2-methylpyrimidine dihydrate ≥98%

MSDS Certificati

2-Amino-4-hydroxy-6-methylpyrimidine ≥98.0% (by HPLC, titration analysis)

Fornitore: TCI EUROPE

Descrizione: 2-Amino-4-hydroxy-6-methylpyrimidine ≥98.0% (by HPLC, titration analysis)

2-Amino-4-hydroxy-6-methylpyrimidine 99%

Fornitore: Thermo Scientific

Descrizione: 2-Amino-4-hydroxy-6-methylpyrimidine 99%

MSDS

2-Amino-4-hydroxy-6-methylpyrimidine 98%

Fornitore: Thermo Scientific

Descrizione: 2-Amino-4-hydroxy-6-methylpyrimidine 98%

MSDS

4-Amino-6-hydroxy-2-methylpyrimidine hydrate ≥98.0% (by titrimetric analysis)

Fornitore: TCI EUROPE

Descrizione: 4-Amino-6-hydroxy-2-methylpyrimidine hydrate ≥98.0% (by titrimetric analysis)

Cocarboxylase ≥98.0% (by titrimetric analysis)

Codice catalogo: (TCIAT0183-5G)

Fornitore: TCI EUROPE

Codice articolo fornitore: T0183-5G

Codice articolo locale: TCIAT0183-5G

Descrizione: Cocarboxylase ≥98.0% (by titrimetric analysis)

UOM: 1 * 5 g

Promo

Non disponibile confezione

2'-Deoxy-5-methylcytidine

Codice catalogo: (APOSOR40355-1G)

Fornitore: Apollo Scientific

Codice articolo fornitore: OR40355-1G

Codice articolo locale: APOSOR40355-1G

Descrizione: 2'-Deoxy-5-methylcytidine

UOM: 1 * 1 g

Promo

Non disponibile confezione

2'-Deoxy-5-methylcytidine ≥98.0% (by HPLC, titration analysis)

Fornitore: TCI EUROPE

Descrizione: 2'-Deoxy-5-methylcytidine ≥98.0% (by HPLC, titration analysis)

Benfotiamine ≥98.0% (by HPLC, titration analysis)

Fornitore: TCI EUROPE

Descrizione: Benfotiamine ≥98.0% (by HPLC, titration analysis)

Descrizione: Benfotiamine is a lipid-soluble form of vitamin B1 (thiamine). <i>in vitro</i>, it corrects defective replication of, and prevents formation of advanced glycosylation end products (AGEs) in, human umbilical vein endothelial cells (HUVECs) grown under high glucose conditions.<i> in vivo</i>, administration of benfotiamine increases nerve conduction velocity (NCV) and prevents microalbuminuria, proteinuria, and formation of AGEs in mice with streptozotocin-induced diabetes.